Literature DB >> 29102703

On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.

Wenqi Wu1, Korbinian Löbmann1, Thomas Rades1, Holger Grohganz2.   

Abstract

Co-amorphous drug delivery systems based on amino acids as co-formers have shown promising potential to improve the solubility and bioavailability of poorly water-soluble drugs. Potential salt formation is assumed to be a key molecular interaction responsible for amorphous stability and increased solubility. However, little is known about the importance of the overall structure of the co-former. In this study, the structurally related amino acids arginine (basic) and citrulline (neutral) were chosen together with four model drugs (acidic furosemide and nitrofurantoin; basic cimetidine and mebendazole) to investigate the importance of salt formation versus structural similarity of co-formers. Drug-amino acid mixtures were ball milled at a molar ratio of 1:1. Generally, arginine showed a higher tendency to successfully form co-amorphous systems with the model drugs compared with citrulline, irrespective of assumed salt formation. Salt forming mixtures showed much higher Tgs, faster dissolution rates, higher solubility and physical stability compared to the corresponding non-salt forming mixtures. In conclusion, structural similarity of the co-formers does not lead to similar co-former performance for a given drug. Salt formation is not a prerequisite for the formation of a co-amorphous system, but if a co-amorphous salt system is formed, improved dissolution rate and physical stability are observed.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arginine; Citrulline; Co-amorphous; Salt formation; Structure

Mesh:

Substances:

Year:  2017        PMID: 29102703     DOI: 10.1016/j.ijpharm.2017.10.057

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Challenges and opportunities of pharmaceutical cocrystals: a focused review on non-steroidal anti-inflammatory drugs.

Authors:  Utsav Garg; Yasser Azim
Journal:  RSC Med Chem       Date:  2021-02-09

Review 2.  Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.

Authors:  Anna Karagianni; Kyriakos Kachrimanis; Ioannis Nikolakakis
Journal:  Pharmaceutics       Date:  2018-07-19       Impact factor: 6.321

3.  Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.

Authors:  Eric Ofosu Kissi; Keyoomars Khorami; Thomas Rades
Journal:  Pharmaceutics       Date:  2019-11-24       Impact factor: 6.321

4.  Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for more robust release profiles.

Authors:  Tu Van Duong; Hanh Thuy Nguyen; Lynne S Taylor
Journal:  Eur J Pharm Biopharm       Date:  2022-04-09       Impact factor: 5.589

5.  Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate.

Authors:  Lin-Lin Pei; Wen-Zhu Yang; Jing-Yuan Fu; Meng-Xi Liu; Ting-Ting Zhang; Dong-Bo Li; Ruo-Yue Huang; Li Zhang; Guang-Neng Peng; Gang Shu; Zhi-Xiang Yuan; Ju-Chun Lin; Wei Zhang; Zhi-Jun Zhong; Ling Zhao; Hua-Lin Fu
Journal:  Drug Des Devel Ther       Date:  2020-02-24       Impact factor: 4.162

Review 6.  Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.

Authors:  Jingwen Liu; Holger Grohganz; Korbinian Löbmann; Thomas Rades; Nele-Johanna Hempel
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.